These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 34290688)

  • 1. QPX7728, An Ultra-Broad-Spectrum B-Lactamase Inhibitor for Intravenous and Oral Therapy: Overview of Biochemical and Microbiological Characteristics.
    Lomovskaya O; Tsivkovski R; Sun D; Reddy R; Totrov M; Hecker S; Griffith D; Loutit J; Dudley M
    Front Microbiol; 2021; 12():697180. PubMed ID: 34290688
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Nelson K; Rubio-Aparicio D; Sun D; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32482673
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Lomovskaya O; Castanheira M; Lindley J; Rubio-Aparicio D; Nelson K; Tsivkovski R; Sun D; Totrov M; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2023 Nov; 67(11):e0044023. PubMed ID: 37800963
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Lomovskaya O; Rubio-Aparicio D; Nelson K; Sun D; Tsivkovski R; Castanheira M; Lindley J; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2021 May; 65(6):. PubMed ID: 33782010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases.
    Tsivkovski R; Totrov M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32152086
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Nelson K; Rubio-Aparicio D; Tsivkovski R; Sun D; Totrov M; Dudley M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32868334
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spectrum of Beta-Lactamase Inhibition by the Cyclic Boronate QPX7728, an Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases: Enhancement of Activity of Multiple Antibiotics against Isogenic Strains Expressing Single Beta-Lactamases.
    Lomovskaya O; Tsivkovski R; Nelson K; Rubio-Aparicio D; Sun D; Totrov M; Dudley MN
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Intrinsic Resistance Mechanisms on Potency of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases in
    Lomovskaya O; Nelson K; Rubio-Aparicio D; Tsivkovski R; Sun D; Dudley MN
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32229498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Ultrabroad-Spectrum Beta-Lactamase Inhibitor QPX7728 Restores the Potency of Multiple Oral Beta-Lactam Antibiotics against Beta-Lactamase-Producing Strains of Resistant
    Lomovskaya O; Rubio-Aparicio D; Tsivkovski R; Loutit J; Dudley M
    Antimicrob Agents Chemother; 2022 Feb; 66(2):e0216821. PubMed ID: 34902261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New β-Lactam-β-Lactamase Inhibitor Combinations.
    Yahav D; Giske CG; Grāmatniece A; Abodakpi H; Tam VH; Leibovici L
    Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33177185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa.
    Lee SY; Gill CM; Nicolau DP;
    J Antimicrob Chemother; 2023 Dec; 78(12):2795-2800. PubMed ID: 37840005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antimicrobial activities of ceftazidime/avibactam, ceftolozane/tazobactam, imipenem/relebactam, meropenem/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections.
    Sader HS; Castanheira M; Duncan LR; Mendes RE
    Int J Infect Dis; 2021 Dec; 113():279-281. PubMed ID: 34670144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales.
    Bonnin RA; Bernabeu S; Emeraud C; Naas T; Girlich D; Jousset AB; Dortet L
    Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients.
    Barbier F; Hraiech S; Kernéis S; Veluppillai N; Pajot O; Poissy J; Roux D; Zahar JR;
    Ann Intensive Care; 2023 Jul; 13(1):65. PubMed ID: 37462830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol: which are the best present and future therapeutic alternatives?
    Le Terrier C; Freire S; Nordmann P; Poirel L
    Eur J Clin Microbiol Infect Dis; 2024 Feb; 43(2):339-354. PubMed ID: 38095831
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Sabet M; Tarazi Z; Griffith DC
    Antimicrob Agents Chemother; 2020 Oct; 64(11):. PubMed ID: 32839224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meropenem-ANT3310, a unique β-lactam-β-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant
    Zalacain M; Achard P; Llanos A; Morrissey I; Hawser S; Holden K; Toomey E; Davies D; Leiris S; Sable C; Ledoux A; Bousquet J; Castandet J; Lozano C; Everett M; Lemonnier M
    Antimicrob Agents Chemother; 2024 Mar; 68(3):e0112023. PubMed ID: 38289044
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Guo Y; Han R; Jiang B; Ding L; Yang F; Zheng B; Yang Y; Wu S; Yin D; Zhu D; Hu F;
    Microbiol Spectr; 2022 Aug; 10(4):e0185422. PubMed ID: 35862963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens.
    Bush K
    Int J Antimicrob Agents; 2015 Nov; 46(5):483-93. PubMed ID: 26498989
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.